The Journal of Practical Medicine >

2026 , Vol. 42 >Issue 13: 2388 - 2395

DOI: https://doi.org/10.3969/j.issn.1006-5725.2026.13.015

Chronic Disease Control

Value of combined detection of serum oxct1 and xirp2 with disease severity and prognosis in children with atopic dermatitis

  • Junlin XIAO ,
  • Guibin WANG ,
  • Junfeng LIU ,
  • Chuofan CHEN ,
  • Xiumei MO ,
  • Dachan CHEN ,
  • Xiaobo YU
Expand
  • 1.The Second Clinical Medical College of Guangzhou University of Chinese Medicine，Guangzhou 510405，Guangdong，China
    2.Department of Dermatology the Second Affiliated Hospital of Guangzhou University of Chinese Medicine（ Guangdong Provincial Hospital of Traditional Chinese Medicine），Guangzhou 510120，Guangdong，China
    3.State Key Laboratory of Proteomics，Beijing Proteome Research Center，National Center for Protein Sciences，Beijing Institute of Lifeomics，Beijing 102206，Beijing，China
    4.Department of Integrative Chinese and Western Medicine，Dermatology Hospital of Southern Medical University（ Guangdong Provincial Dermatology Hospital），Guangzhou 520091，Guangdong，China

Received date: 2026-04-09

  Online published: 2026-07-14

Fold

Abstract

Objective To explore the relationship between serum 3-oxoacid CoA-transferase 1 （OXCT1）， Xin actin-binding repeat-containing protein 2 （XIRP2）， and the severity and prognosis of atopic dermatitis （AD） in children. Methods Thirty children with moderate-to-severe AD who were treated at the Dermatology Outpatient Department of Guangdong Provincial Hospital of Chinese Medicine were enrolled in the observation group. According to the severity of their conditions， they were divided into a moderate group （n = 15） and a severe group （n = 15）. After 12 weeks of treatment， they were further classified into a good prognosis group （n = 20） and a poor prognosis group （n = 10）. Meanwhile， 30 healthy children with no previous history of allergic diseases were selected as the control group. Serum proteomic levels were measured by data-independent acquisition mass spectrometry （DIA-MS） to determine the expression levels of OXCT1 and XIRP2. Clinical data， immunoglobulin E （IgE） levels， and eosinophil counts of the AD children were collected. Logistic regression analysis was used to identify the factors influencing the poor prognosis in children with AD. Receiver operating characteristic （ROC） curve analysis was carried out to evaluate the value of serum OXCT1 and XIRP2， either individually or in combination. Results When compared with the control group， the serum OXCT1 level in the observation group showed a significant increase， and the XIRP2 level presented a significant decrease （P 0.05）. Serum OXCT1 levels gradually rose as the disease severity worsened， while serum XIRP2 levels gradually declined （P 0.05）. In comparison with the good prognosis group， there were no statistically significant differences in clinical data， IgE levels， or eosinophil counts in the poor prognosis groups （P 0.05）. Serum XIRP2 was identified as an independent risk factor for poor prognosis in children with AD， whereas serum OXCT1 was identified as an independent protective factor （P 0.05）. The area under the ROC curve （AUC） for poor prognosis was 0.940 for OXCT1， 0.885 for XIRP2， and 0.945 for the combination of both markers. The combined prediction AUC remained higher than that of either marker alone. Conclusions Serum OXCT1 levels were significantly elevated， and XIRP2 levels were significantly decreased in children with atopic dermatitis. These two factors may play biological roles at different stages of disease development and prognosis. OXCT1 functions as a protective factor， whereas XIRP2 serves as a risk factor for poor prognosis. The combined assessment of serum OXCT1 and XIRP2 shows good predictive efficacy for the prognosis of children with atopic dermatitis.

Key words： pediatric atopic dermatitis; 3-oxoacid CoA-transferase 1; Xin actin-binding repeat-containing protein 2

Cite this article

Junlin XIAO , Guibin WANG , Junfeng LIU , Chuofan CHEN , Xiumei MO , Dachan CHEN , Xiaobo YU . Value of combined detection of serum oxct1 and xirp2 with disease severity and prognosis in children with atopic dermatitis[J]. The Journal of Practical Medicine, 2026 , 42(13) : 2388 -2395 . DOI: 10.3969/j.issn.1006-5725.2026.13.015

References

[1] CHU D K， SCHNEIDER L， ASINIWASIS R N， et al. Atopic dermatitis （eczema） guidelines： 2023 American Academy of Allergy， Asthma and Immunology/American College of Allergy， Asthma and Immunology Joint Task Force on Practice Parameters GRADE?and Institute of Medicine?based recommendations［J］. Ann Allergy Asthma Immunol， 2024， 132（3）： 274-312. doi：10.1016/j.anai.2023.11.009 .
[2] CHUNG W K， VAN TILBORG-DEN BOEFT M， DE SCHEPPER E， et al. Prevalence of childhood atopic triad： Atopic dermatitis， asthma and allergic rhinitis， a Rijnmond Primary Care database study［C］//Child and Adolescent Health. American Academy of Family Physicians， 2023： 4788. doi：10.1370/afm.22.s1.4788 .
[3] 赵鋆， 马春艳， 邓丹， 等. 儿童特应性皮炎（湿疹）中医药干预方案专家共识［J］. 中国中西医结合儿科学， 2024， 16（3）： 185-190.doi： 10.3969/j.issn.1674-3865.2024.03.001 .
[4] 中华医学会皮肤性病学分会， 中国中西医结合学会皮肤性病专业委员会， 中国医师协会皮肤科医师分会. 中国甲真菌病诊疗指南（2015年版）［J］. 中国真菌学杂志， 2015， 10（2）： 118-125. doi： 10.3969/j.issn.1673-3827.2015.02.018 .
[5] MOREIRAS-ARIAS N， NIETO-FONTARIGO J J， SALGADO F J， et al. Novel Therapeutic Strategies for Atopic Dermatitis： Biomarker Modulation and Clinical Implications. A Systematic Review［J］. Clin Rev Allergy Immunol， 2026， 69（1）：4. doi： 10.1007/s12016-025-09129-z .
[6] 周文娣， 林佳敏， 琚岱晨， 等. 肺癌合并肺结核的蛋白组学图谱及差异表达蛋白功能分析［J］. 实用医学杂志， 2024， 40（13）： 1814-1821. doi：10.3969/j.issn.1006-5725.2024.13.009 .
[7] KURGAN N， KJ?RGAARD LARSEN J， DESHMUKH A S. Harnessing the power of proteomics in precision diabetes medicine［J］. Diabetologia， 2024， 67（5）： 783-797. doi：10.1007/s00125-024-06097-5 .
[8] FEHR D， HUYNH-TRAN V H， MAINTZ L， et al. Deciphering the connection between atopic dermatitis and cardiovascular diseases： Analysis of clinical associations and cardiometabolic proteins［J］. Allergy， 2025， 80（8）： 2187-2200. doi：10.1111/all.16588 .
[9] JIN S P， KIM H， MOON J H， et al. Proteomic analysis of cardiovascular disease-associated proteins in Korean patients with moderate-to-severe atopic dermatitis［J］. World Allergy Organ J， 2024， 17（8）： 100949. doi：10.1016/j.waojou.2024.100949 .
[10] FACHERIS P， ROSA J C DA， PAGAN A D， et al. Age of onset defines two distinct profiles of atopic dermatitis in adults［J］. Allergy， 2023， 78（8）： 2202-2214. doi：10.1111/all.15741 .
[11] GLICKMAN J W， DAVID E， SHOKRIAN N， et al. Large-scale blood proteomic analysis across different inflammatory skin conditions reveals extensive immune dysregulation with distinct biomarker profiles［J］. Allergy， 2026， 81（2）： 524-538. doi：10.1111/all.70157 .
[12] GOLEVA E， BERDYSHEV E， KREIMER S， et al. Longitudinal integrated proteomic and metabolomic skin changes in patients with atopic dermatitis treated with dupilumab［J］. J Allergy Clin Immunol， 2025， 155（5）： 1536-1546. doi：10.1016/j.jaci.2025. 01.020 .
[13] NAKAJIMA S， NAKAMIZO S， NOMURA T， et al. Integrating multi-omics approaches in deciphering atopic dermatitis pathogenesis and future therapeutic directions［J］. Allergy， 2024， 79（9）： 2366-2379. doi：10.1111/all.16183 .
[14] SONG B， NING X， GUO L， et al. Comparative proteomics analysis reveals distinct molecular phenotype and biomarkers in patients with erythrodermic atopic dermatitis and erythrodermic psoriasis［J］. Inflammation， 2025， 48（1）： 331-345. doi：10.1007/s10753-024-02078-3 .
[15] SCHMID-GRENDELMEIER P， GOODERHAM M J， HARTMANN K， et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies［J］. Allergy， 2024， 79（1）： 174-183. doi：10.1111/all.15952 .
[16] HüBENTHAL M， DAI C， BROWN S J， et al. Mapping SCORing of Atopic Dermatitis （SCORAD） and objective SCORAD to the Eczema Area and Severity Index to facilitate large-scale meta-analyses of molecular data［J］. Br J Dermatol， 2024， 191（4）： 637-639. doi：10.1093/bjd/ljae232 .
[17] RUGE I F， HALLING A S， RASMUSSEN RINNOV M， et al. Infant palmar hyperlinearity and type 2 inflammatory markers predict atopic dermatitis at 1?year of age［J］. Acad Dermatol Venereol， 2025， 39（12）： 2079-2087. doi：10.1111/jdv.20824 .
[18] 中华医学会皮肤性病学分会免疫学组. 特应性皮炎的全程管理共识［J］. 中华皮肤科杂志， 2023， 56（1）： 5-15. doi：10.35541/cjd.20220618 .
[19] TIAN J， ZHANG D， YANG Y， et al. Global epidemiology of atopic dermatitis： A comprehensive systematic analysis and modelling study［J］. Br J Dermatol， 2023， 190（1）： 55-61. doi：10.1093/bjd/ljad339 .
[20] 陈祥， 蒋最明， 李胜， 等. 特应性皮炎患者血清C型凝集素结构域家族4成员G水平及其意义［J］. 实用医学杂志， 2023， 39（21）： 2808-2811. doi：10.3969/j.issn.1006-5725.2023.21.019 .
[21] QIN W， HU W， GENG Y. The function and mechanism of OXCT1 in tumor progression as a critical ketone body metabolic enzyme［J］. Biomolecules， 2026， 16（1）： 4. doi：10.3390/biom16010004 .
[22] TABATABAEI DAKHILI S A， YANG K， NEBAIHI H AL， et al. Development of a succinyl CoA： 3-ketoacid CoA transferase inhibitor selective for peripheral tissues that improves glycemia in obesity［J］. iScience， 2025， 28（5）： 112336. doi：10.1016/j.isci.2025.112336 .
[23] BUCKEL W， DORN U， SEMMLER R. Glutaconate CoA-transferase from Acidaminococcus fermentans ［J］. Eur J Biochem， 1981， 118（2）： 315-321. doi：10.1111/j.1432-1033.1981.tb06404.x .
[24] BEROD L， FRIEDRICH C， NANDAN A， et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells［J］. Nat Med， 2014， 20（11）： 1327-1333. doi：10.1038/nm.3704 .
[25] NAHM D H. Regulatory T cell-targeted immunomodulatory therapy for long-term clinical improvement of atopic dermatitis： Hypotheses and perspectives［J］. Life， 2023， 13（8）： 1674. doi：10.3390/life13081674 .
[26] 秦成， 王芳， 张卓， 等. 连术饮对特应性皮炎小鼠Th17/Treg免疫失衡及芳香烃受体表达的影响［J］. 中国皮肤性病学杂志， 2024， 38（8）： 837-848. doi：10.13735/j.cjdv.1001-7089. 202311119 .
[27] 刘懿， 陈尧， 李小平. 辅助性和调节性T淋巴细胞亚群与特应性皮炎严重程度的相关性［J］. 中国皮肤性病学杂志， 2024， 38（11）： 1220-1228. doi：10.13735/j.cjdv.1001-7089.202303032 .
[28] WINDER W W， HOLLOSZY J O， BALDWIN K M. Enzymes involved in ketone utilization in different types of muscle： Adaptation to exercise［J］. Eur J Biochem， 1974， 47（3）： 461-467. doi：10.1111/j.1432-1033.1974.tb03713.x .
[29] NAGAO M， TOH R， IRINO Y， et al. β-Hydroxybutyrate elevation as a compensatory response against oxidative stress in cardiomyocytes［J］. Biochem Biophys Res Commun， 2016， 475（4）： 322-328. doi：10.1016/j.bbrc.2016.05.097 .
[30] SCHUGAR R C， MOLL A R， ANDRé D’AVIGNON D， et al. Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling［J］. Mol Metab， 2014， 3（7）： 754-769. doi：10.1016/j.molmet.2014.07.010 .
[31] MAALOUF M， SULLIVAN P G， DAVIS L， et al. Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation［J］. Neuroscience， 2007， 145（1）： 256-264. doi：10.1016/j.neuroscience.2006.11.065 .
[32] DONG Y N， MESAROS C， XU P， et al. Frataxin controls ketone body metabolism through regulation of OXCT1［J］. PNAS Nexus， 2022， 1（3）： pgac142. doi：10.1093/pnasnexus/pgac142 .
[33] YANG S， AHN S， KIM J. 3-Oxoacid CoA transferase 1 as a therapeutic target gene for cisplatin-resistant ovarian cancer［J］. Oncol Lett， 2018， 15（2）： 2611-2618.doi： 10.3892/ol. 2017. 7560 .
[34] LEE C L， HUANG C J， YANG S H， et al. Discovery of genes from feces correlated with colorectal cancer progression［J］. Oncol Lett， 2016， 12（5）： 3378-3384. doi：10.3892/ol.2016.5069 .
[35] HUANG D， LI T， WANG L， et al. Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress［J］. Cell Res， 2016， 26（10）： 1112-1130. doi：10.1038/cr.2016.109 .
[36] ZHANG Q， LIANG Z， GAO Y， et al. Differentially expressed mitochondrial genes in breast cancer cells： Potential new targets for anti-cancer therapies［J］. Gene， 2017， 596： 45-52. doi：10.1016/j.gene.2016.10.005 .
[37] ZHONG C， YU Q， PENG Y， et al. Novel LncRNA OXCT1-AS1 indicates poor prognosis and contributes to tumorigenesis by regulating miR-195/CDC25A axis in glioblastoma［J］. J Exp Clin Cancer Res， 2021， 40（1）： 123. doi：10.1186/s13046-021-01928-4 .
[38] MARTINEZ-OUTSCHOORN U E， LIN Z， WHITAKER-MENEZES D， et al. Ketone body utilization drives tumor growth and metastasis［J］. Cell Cycle， 2012， 11（21）： 3964-3971. doi：10.4161/cc.22137 .
[39] WANG Q， LIN J L， ERIVES A J， et al. New insights into the roles of Xin repeat-containing proteins in cardiac development， function， and disease［M］. Int Rev Cell Mol Biol， 2014， 310： 89-128. doi:10.1016/b978-0-12-800180-6.00003-7
[40] NIELSEN M S， VAN OPBERGEN C J M， VAN VEEN T A B， et al. The intercalated disc： A unique organelle for electromechanical synchrony in cardiomyocytes［J］. Physiol Rev， 2023， 103（3）： 2271-2319. doi：10.1152/physrev.00021.2022 .
[41] SCHAARSCHMIDT H， ELLINGHAUS D， RODRíGUEZ E， et al. A genome-wide association study reveals 2 new susceptibility loci for atopic dermatitis［J］. J Allergy Clin Immunol， 2015， 136（3）： 802-806. doi：10.1016/j.jaci.2015.01.047 .
[42] WANG D Z， REITER R S， LIN J L， et al. Requirement of a novel gene， Xin， in cardiac morphogenesis［J］. Development， 1999， 126（6）： 1281-1294. doi：10.1242/dev.126.6.1281 .
[43] GUSTAFSON-WAGNER E A， SINN H W， CHEN Y L， et al. Loss of mXinα， an intercalated disk protein， results in cardiac hypertrophy and cardiomyopathy with conduction defects［J］. Am J Physiol Heart Circ Physiol， 2007， 293（5）： H2680-H2692. doi：10.1152/ajpheart.00806.2007 .
[44] CHEN X， SHEVTSOV S P， HSICH E， et al. The β-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy［J］. Mol Cell Biol， 2006， 26（12）： 4462-4473. doi：10.1128/mcb. 02157-05 .
[45] QU J， ZHOU J， XIAN P Y， et al. Cardiac-specific haploinsufficiency of β-catenin attenuates cardiac hypertrophy but enhances fetal gene expression in response to aortic constriction［J］. J Mol Cell Cardiol， 2007， 43（3）： 319-326. doi：10.1016/j.yjmcc.2007. 06.006 .
[46] MCCALMON S A， DESJARDINS D M， AHMAD S， et al. Modulation of angiotensin II?mediated cardiac remodeling by the MEF2A target gene Xirp2［J］. Circ Res， 2010， 106（5）： 952-960. doi：10.1161/circresaha.109.209007 .
[47] PACHOLSKY D， VAKEEL P， HIMMEL M， et al. Xin repeats define a novel actin-binding motif［J］. J Cell Sci， 2004， 117（22）： 5257-5268. doi：10.1242/jcs.01406 .
[48] PANIGRAHI A K， ZHANG N， OTTA S K， et al. A cohesin–RAD21 interactome［J］. Biochem J， 2012， 442（3）： 661-670. doi：10.1042/bj20111745 .
[49] SCALA E， MADONNA S， ABENI D， et al. A microarray-based IgE-molecular mimicry index （IgE-MMI）： A biomarker for disease severity， clinical phenotypes， and therapeutic response in atopic dermatitis？［J］. Allergy， 2024， 79（12）： 3415-3429. doi：10.1111/all.16377 .
Options
Outlines

/

〈 〉